Abstract：OBJECTIVE: To assess the therapeutic effects and safety of different doses of immunoglobulin in the treatment of Kawasaki disease. METHODS: The papers related to the treatment of Kawasaki disease were electronically searched in the databases of PubMed, EMBASE, Cochrane Library, CNKI, VIP and Wanfang. Randomized clinical trials (RCT) on the treatment of Kawasaki disease with different doses of immunoglobulin were included and assessed for quality. A Mata analysis was performed by RevMan 5.0. RESULTS: Twenty-eight RCTs involved 2596 cases were included. The results of Meta analysis showed that there were no significant differences in the incidences of coronary artery injuries at various phases, adverse effects and fever disappearance time between the immunoglobulin treatment groups at the doses of 1 g/(kg?d) for 1-2 days and 2 g/(kg?d) for single use. The fever disappearance time in the immunoglobulin treatment group at the dose of 1 g/(kg?d) for 1-2 days was significantly shorter than that in the immunoglobulin treatment group at the dose of 400 mg/(kg?d) for 4-5 days, but there were no significant differences in the incidences of coronary artery injuries at the acute phase and 6 months after treatment and adverse effects between the two groups. The incidence of coronary artery injuries at the acute phase and 6 months was lower and the fever disappearance time was shorter in the immunoglobulin treatment group at the dose of 2 g/(kg?d) for single use than those in the immunoglobulin treatment group at the dose of 400 mg/(kg?d) for 4-5 days, but there were no significant differences in the incidences of coronary artery injuries at the subacute phase and 12 months after treatment and adverse effects between the two groups. CONCLUSIONS: There are similar therapeutic effects for Kawasaki disease between the immunoglobulin treatment groups at the doses of 1 g/(kg?d) for 1-2 days and 2 g/(kg?d) for single use. The fever disappearance time in the two groups is shorter than that in the treatment group at the dose of 400 mg /(kg?d) for 4-5 days.
CHEN Jing,MA Bin,LIN Li-Xing et al. Treatment of Kawasaki disease by different doses of immunoglobulin: a Mata analysis of therapeutic effects[J]. CJCP, 2011, 13(8): 638-643.
［1］Kim DS. Kawasaki disease［J］. Yonsei Med J, 2006, 47(6)：759-772.
［2］Klassen TP, Rowe PC, Gafni A. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome［J］. J Pediatr, 1993, 122(4)：538-542.
［3］Cha S, Yoon M, Ahn Y, Han M, Yoon KL. Risk factors for failure of initial intravenous immunoglobulin treatment in Kawasaki disease［J］. J Korean Med Sci, 2008, 23(4)：718-722.
［4］Liang CM, Lee PC, Hwang BT, Lu JH, Wang PY, Lien CH, et al. Comparison of different types and regimens of intravenous immune globulin (IVIG) in patients with Kawasaki disease［J］. Acta Cardiol Sin, 2004, 20(1):15-20.
［5］Rigante D, Valentini P, Rizzo D, Leo A, De Rosa G, Onesimo R, et al. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome［J］. Rheumatol Int, 2010, 30(6)：841-846.
［6］Sakata K, Hamaoka K, Ozawa S, Niboshi A, Yoshihara T, Nishiki T, et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease［J］. Eur J Pediatr, 2007,166(6): 565-571.
［8］Baba R. Effect of immunoglobulin therapy on blood viscosity and potential concerns of thromboembolism, especially in patients with acute Kawasaki disease［J］. Recent Pat Cardiovasc Drug Discov, 2008, 3(2): 141-144.
［9］Shulman ST. Kawasaki disease and IVIG: what's going on here? Immunotherapy with intravenous immunoglobulins ［M］. San Diego：Academic Press, 1991: 261-268.
［10］Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 ［updated February 2008］［DB/OL］. The Cochrane Collaboration, 2008. Available at www. Cochrane-handbook org.
［11］Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome［J］. N Engl J Med, 1991, 324(23): 1633-1639.
［13］Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, et al. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness［J］. Pediatr Int, 1999, 41(1):1-7.
［14］Saulsbury FT. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome［J］. Clin Pediatr (Phila), 2002, 41(8): 597-601.
［39］Mofi M, Miyamae T, Imgawa T, Katakura S, Kimura K, Yokota S. Meta-analysis of the results of intravenous gamma-globulin treatment of coronary artery lesions in Kawasaki disease［J］. Mod Rheumatol, 2004,14(5): 361-366.
